Keytruda 100MG/4ML 1S
Ended Awarded Last action
- Contract number
- SPE2DR26FBTGZ
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $41,790
Award facts
- Contract value 100% obligated
- $41,789.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $41,789.90 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda (pembrolizumab) 100mg/4ml. The delivery order, issued on December 12, 2025, with an ultimate completion date of January 6, 2026, was issued without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business status and established performance record to support Department of Defense healthcare operations.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy. The underlying IDC, designated as contract SPE2DR and awarded on November 13, 2025, carries a $499,999,999 ceiling value and extends through December 31, 2036, with a 30-month base period followed by three 30-month option periods. The PPV-G GEN V program positions DMS Pharmaceutical Group as a regional prime vendor contractor authorized to supply a comprehensive range of pharmaceutical products, including branded and generic prescription medications, biologics, and medical consumables, to support the recurring medical supply needs of military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FBTGZ?
SPE2DR26FBTGZ was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 12, 2025.
How much is contract SPE2DR26FBTGZ worth?
The government has obligated $41,790 on SPE2DR26FBTGZ.
Is contract SPE2DR26FBTGZ an order under another contract?
Yes. SPE2DR26FBTGZ is a delivery order under SPE2DR25D9628, an indefinite delivery contract.
Was contract SPE2DR26FBTGZ competed?
The extent of competition for SPE2DR26FBTGZ was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award